Terns Pharma

TERNS PHARMACEUTICALS INC

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.

Display,Of,Stock,Market,Quotes

ACLS

CASY

CSAN

INSM

LEGN

MTSR

NVTS

NWTN

PLUG

QUBT

RXRX

TERN

TSLA

Insmed, Tesla, Casey&#39;s General Stores And Other Big Stocks Moving Higher On Tuesday

Bernie's Concerns With Healthcare Costs

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

AMRN

Top 3 Health Care Stocks You&#39;ll Regret Missing In Q4

Wall Street

Initiation

Analyst Ratings

ALMS

BRZE

ELVN

INTS

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharmaceuticals Inc

Tern PLC

TERNIUM ARGENTINA S A by TERNIUM ARGENTINA S A

Terna Energy SA

Terna Energy SA ADR

TRASMISSIONE ELECTR ORD by Terna Rete Elettrica Nazionale SPA

Terna SpA

TERNA RETE ELETTRICA ADR by Terna Rete Elettrica Nazionale SPA

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares, USD1.00 par value)

Ternium SA

Ternoa

Health Care

Press Releases

General

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Earnings

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Alumis

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

Maze Therapeutics

MBX Biosciences

Nektar Therapeutics

Omeros

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

scPharmaceuticals

Septerna

SIGA Technologies

SNDL

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Third Harmonic Bio

Tilray Brands

Tvardi Therapeutics

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

BMO Capital

JMP Securities

Oppenheimer

HC Wainwright & Co.

Terayon Comm

Comments

Terns Pharma

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell